D. Lane

H. Ireland, D. Lane, E. Anastassiades, 1990, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The Anticoagulant Effect of Heparinoid Org 10172 During Haemodialysis: An Objective Assessment

H. Ireland, D. Lane, H. Ireland, 1986, Thrombosis and Haemostasis.

The neutralisation of heparin by Trasylol.

D. Lane, F. E. Preston, R. Davies, 1980, Thrombosis research.

Thrombin Production, Inactivation and Expression during Open Heart Surgery Measured by Assays for Activation Fragments Including a New ELISA for Prothrombin Fragment F1+2

H. Philippou, M. Boisclair, D. Lane, 1993, Thrombosis and Haemostasis.

Neutralization of heparin by Trasylol.

I. Macgregor, D. Lane, F. E. Preston, 1994, Annals of Thoracic Surgery.

Inherited Thrombophilia: Part 1

P. Mannucci, F. Rosendaal, J. Miletich, 1996, Thrombosis and Haemostasis.

I. KINETICS OF CLEARANCE FROM THE CIRCULATION OF MAN FOLLOWING INTRAVENOUS INJECTION

D. Lane, R. Michalski, V. Kakkar, 1999 .

EPIDEMIOLOGY OF COAGULATION FACTORS, INHIBITORS AND ACTIVATION MARKERS: THE THIRD GLASGOW MONICA SURVEY I. ILLUSTRATIVE REFERENCE RANGES BY AGE, SEX AND HORMONE USE

M. Woodward, H. Tunstall-Pedoe, C. Morrison, 1997, British journal of haematology.

Correcting the hemophilic imbalance.

D. Lane, 2017, Blood.

The causality assessment of adverse drug reactions using a bayesian approach

C. Naranjo, M. Kramer, D. Lane, 1987 .

European Stroke Initiative Recommendations for Stroke Management

G. Hankey, M. Hommel, J. Perret, 2000, Cerebrovascular Diseases.

The central role of thrombin in hemostasis

D. Lane, J. Crawley, S. Zanardelli, 2007, Journal of thrombosis and haemostasis : JTH.

Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex.

S. Rezende, D. Lane, R. Simmonds, 2004, Blood.

Antithrombin: structure, genomic organization, function and inherited deficiency.

D. Lane, R. Casó, 1989, Bailliere's clinical haematology.

Heparin: Chemical and Biological Properties Clinical Applications

D. Lane, U. Lindahl, 1989 .

Impaired cotranslational processing as a mechanism for type I antithrombin deficiency.

G. Leone, D. Lane, R. Olds, 1998, Blood.

CALCIUM BINDING TO ANTICOAGULANT PROTEIN S. ROLE OF THE FOURTH EGF MODULE

S. Linse, J. Stenflo, S. Rezende, 2012 .

Non-anticoagulant uses of heparin.

D. Lane, L. Adams, 1993, The New England journal of medicine.

Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening

S. Thein, P. Mannucci, K. Bauer, 1993, British journal of haematology.

Novel point mutations leading to type 1 antithrombin deficiency and thrombosis

G. Leone, S. Thein, J. Cazenave, 1991, British journal of haematology.

Structural and Functional Implications of the Intron/Exon Organization of the Human Endothelial Cell Protein C/Activated Protein C Receptor (EPCR) Gene: Comparison With the Structure of CD1/Major Histocompatibility Complex 1 and 2 Domains

D. Lane, Rachel E. Simmonds, David A. Lane, 1999, Blood.

Genetic and phenotypic analysis of a large (122-member) protein S-deficient kindred provides an explanation for the familial coexistence of type I and type III plasma phenotypes.

B. Dahlbäck, D. Lane, H. Ireland, 1997, Blood.

Autoantibodies to thrombin directed against both of its cryptic exosites

P. Collins, D. Lane, L. Mollica, 2005, British journal of haematology.

Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive technique.

C. Francis, V. Marder, D. Lane, 1985, Blood.

A HEPARIN ANALOGUE WITH SPECIFIC ACTION ON ANTITHROMBIN III

V. Kakkar, D. Lane, D. Thomas, 1977, The Lancet.

Detection of Enhanced In Vivo Platelet α-Granule Release in Different Patient Groups - Comparison of β-Thromboglobulin, Platelet Factor 4 and Thrombospondin Assays

H. Ireland, D. Lane, J. Dawes, 1984, Thrombosis and Haemostasis.

The roles of factor Va and protein S in formation of the activated protein C/protein S/factor Va inactivation complex

D. Lane, Salvatore Santamaria, J. Ahnström, 2019, Journal of thrombosis and haemostasis : JTH.

TFPI cofactor function of protein S: essential role of the protein S SHBG-like domain.

B. Dahlbäck, S. Rezende, D. Lane, 2014, Blood.

Acquired Dysfibrinogenemia in Acute and Chronic Liver Disease

V. Kakkar, R. Williams, D. Lane, 1977, Thrombosis and Haemostasis.

Interaction of factor V Leiden with inherited anti-thrombin deficiency

P. Reitsma, J. Vandenbroucke, F. Rosendaal, 1995 .

Comparison of Heparin and a Semi‐synthetic Heparin Analogue, A73025

D. Lane, R. Michalski, V. Kakkar, 1977, British journal of haematology.

Hereditary antithrombin deficiency: heterogeneity of the molecular basis and mortality in Dutch families.

P. Reitsma, J. Vandenbroucke, F. Rosendaal, 1994, Blood.

(ATT) trinucleotide repeats in the antithrombin gene and their use in determining the origin of repeated mutations

S. Thein, I. Pabinger, D. Lane, 1994, Human mutation.

Complete nucleotide sequence of the antithrombin gene: evidence for homologous recombination causing thrombophilia.

G. Leone, S. Thein, V. De Stefano, 1993, Biochemistry.

Effect of dextran on clotting time: steric exclusion accelerates fibrin monomer polymerisation.

V. Kakkar, D. Lane, M. Rampling, 1976, Thrombosis research.

Analgesic use, blood dyscrasias, and case-control pharmacoepidemiology. A critique of the International Agranulocytosis and Aplastic Anemia Study.

T. Hutchinson, M. Kramer, D. Lane, 1987, Journal of chronic diseases.

Characterization of peptides cleaved by plasmin from the C-terminal polymerization domain of human fibrinogen.

C. Southan, H. Morris, M. Panico, 1985, The Journal of biological chemistry.

Thrombin-induced fibrinopeptide B release from normal and variant fibrinogens: influence of inhibitors of fibrin polymerization.

K. Preissner, W. Ruf, D. Lane, 1988, Biochimica et biophysica acta.

In vivo platelet release reaction in patients with heart valve prosthesis.

J. Westwick, V. Kakkar, A. Girolami, 1980, Haemostasis.

Antithrombotic Properties of Dermatan Sulphate (MF 701) in Haemodialysis for Chronic Renal Failure

M. Boisclair, H. Ireland, D. Lane, 1992, Thrombosis and Haemostasis.

Proteolysis of fibrinogen in healthy volunteers following major and minor vivo plasminogen activation.

C. Prowse, H. Ireland, D. Lane, 1982, Thrombosis research.

Prolonged thrombin clotting times in liver disease.

M. Scully, V. Kakkar, D. Lane, 1977, Thrombosis research.

Clarification of the Risk for Venous Thrombosis Associated with Hereditary Protein S Deficiency by Investigation of a Large Kindred with a Characterized Gene Defect

B. Dahlbäck, P. García de Frutos, D. Lane, 1998, Annals of Internal Medicine.

Antithrombin III: summary of first database update.

S. Thein, D. Lane, R. Olds, 1994, Nucleic acids research.

and the protein S-C4b binding protein complex Coagulation, inflammation, and apoptosis: different roles for protein S

S. Rezende, D. Lane, R. Simmonds, 2013 .

Identification of 19 protein S gene mutations in patients with phenotypic protein S deficiency and thrombosis. Protein S Study Group.

D. Lane, H. Ireland, R. Simmonds, 1996, Blood.

Laminin G1 residues of protein S mediate its TFPI cofactor function and are competitively regulated by C4BP

D. Lane, Salvatore Santamaria, J. Crawley, 2021, Blood advances.

Identification of functionally important residues in TFPI Kunitz domain 3 required for the enhancement of its activity by protein S.

D. Lane, J. Ahnström, J. Crawley, 2012, Blood.

Activated protein C cofactor function of protein S: a critical role for Asp95 in the EGF1-like domain.

B. Dahlbäck, S. Rezende, D. Lane, 2010, Blood.

Acquired dysfibrinogenaemia masquerading as disseminated intravascular coagulation in acute pancreatitis.

M. Greaves, F. Preston, D. Lane, 1988, Journal of clinical pathology.

Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the Aα 16 Arg → His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide

C. Southan, A. Henschen, D. Lane, 1983 .

Familial Overexpression of b Antithrombin Caused by an Asn 135 Thr Substitution

L. Hananeia, T. Bayston, H. Ireland, 1999 .

Antithrombin III Northwick Park: demonstration of an inactive high MW complex with increased affinity for heparin

H. Ireland, D. Lane, E. Thompson, 1987, British journal of haematology.

Antithrombin III Budapest: a single amino acid substitution (429Pro to Leu) in a region highly conserved in the serpin family.

H. Morris, S. Thein, M. Panico, 1992, Blood.

Antithrombin Budapest 3 An antithrombin variant with reduced heparin affinity resulting from the substitution L99F

M. Boisclair, D. Lane, S. Thein, 1992, FEBS letters.

Use of synthetic oligonucleotides in the characterization of antithrombin III Northwick Park (393 CGT----TGT) and antithrombin III Glasgow (393 CGT----CAT).

S. Thein, D. Lane, 1988, Blood.

Platelet-derived heparin neutralizing proteins.

D. Lane, 1985, Advances in experimental medicine and biology.

A frameshift mutation leading to type 1 antithrombin deficiency and thrombosis.

T. Barbui, S. Thein, D. Lane, 1990, Blood.

A common point mutation producing type 1A antithrombin III deficiency: AT129 CGA to TGA (Arg to Stop).

T. Barbui, S. Thein, A. Girolami, 1991, Thrombosis research.

ADAMTS‐13 and von Willebrand factor: a dynamic duo

D. Lane, K. South, D. Lane, 2017, Journal of thrombosis and haemostasis : JTH.

Adverse events following immunization: assessing probability of causation.

David A. Lane, G. Fenichel, D. Lane, 1989, Pediatric neurology.

Causal propositions in clinical research and practice.

David A. Lane, M. Kramer, D. Lane, 1992, Journal of clinical epidemiology.

Should blood cultures be obtained in the evaluation of young febrile children without evident focus of bacterial infection? A decision analysis of diagnostic management strategies.

M S Kramer, M. Kramer, D. Lane, 1989, Pediatrics.

Regulation of the human endothelial cell protein C receptor gene promoter by multiple Sp1 binding sites.

G. Follows, C. Bonifer, P. Cockerill, 2003, Blood.

N-linked glycan stabilization of the VWF A2 domain.

C. Lynch, D. Lane, 2016, Blood.

THROMBOSIS AND HEMOSTASIS N-linked glycan stabilization of the VWF A 2 domain

C. Lynch, D. Lane, 2016 .

Control of VWF A2 domain stability and ADAMTS13 access to the scissile bond of full-length VWF.

C. Lynch, D. Lane, B. Luken, 2014, Blood.

The importance of vicinal cysteines, C1669 and C1670, for von Willebrand factor A2 domain function.

J. Emsley, D. Lane, J. Crawley, 2010, Blood.

Roles of Low Specificity and Cofactor Interaction Sites on Thrombin during Factor XIII Activation

Lawrence Leung, Helen Philippou, P. Grant, 2003, Journal of Biological Chemistry.

Molecular diversity and thrombotic risk in protein S deficiency: The PROSIT study

M. Margaglione, P. Bucciarelli, G. Castaman, 2005, Human mutation.

The effect of heparin on the inositol 1,4,5‐trisphosphate receptor in rat liver microsomes Dependence on sulphate content and chain length

M. Bootman, D. Lane, U. Lindahl, 1989, FEBS letters.

A microtitre plate ELISA to measure thrombin‐antithrombin complex using pan‐specific antibodies

M. Boisclair, D. Lane, 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Biphasic activation of complement and fibrinolysis during the human nasal allergic response

C. Hawrylowicz, R. Thwaites, P. Openshaw, 2018, The Journal of allergy and clinical immunology.

Risk Factors for Cardiovascular Disease in IDDM: A Study of Identical Twins

R. Leslie, S. Dubrey, D. Lane, 1994, Diabetes.

The scientific basis for selection of measures of thrombogenicity.

D. Lane, S. Bowry, 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Low affinity heparin is an antithrombotic agent.

D. Lane, J. Lormeau, A. Davies, 1994, Thrombosis and haemostasis.

Genetic and Phenotypic Variability between Families with Hereditary Protein S Deficiency

B. Dahlbäck, M. Laffan, S. Rezende, 2002, Thrombosis and Haemostasis.

Chapter 2 Plasma ADAMTS 13 levels and the risk of myocardial infarction : an individual patient data meta-analysis

F. Leebeek, B. Siegerink, D. Lane, 2017 .

The elderly on dialysis: some considerations in compliance.

D. Lane, P. Mckevitt, J. F. Jones, 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Soluble high-molecular-weight E fragments in the plasmin-induced degradation products of cross-linked human fibrin.

P. Gaffney, D. Lane, M. Brasher, 1975, Clinical science and molecular medicine.

A method for characterising serum fibrinogen and fibrin degradation products.

M. Scully, V. Kakkar, D. Lane, 1976, Thrombosis Research.

Characterization of Serum Fibrinogen and Fibrin Fragments Produced during Disseminated Intravascular Coagulation

M. Ross, V. Kakkar, F. Preston, 1978, British journal of haematology.

EPIDEMIOLOGY OF COAGULATION FACTORS, INHIBITORS AND ACTIVATION MARKERS: THE THIRD GLASGOW MONICA SURVEY II. RELATIONSHIPS TO CARDIOVASCULAR RISK FACTORS AND PREVALENT CARDIOVASCULAR DISEASE

M. Woodward, H. Tunstall-Pedoe, C. Morrison, 1997, British journal of haematology.

The ADAMTS13–VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension

J. Barberà, M. Simpson, M. Bleda, 2019, European Respiratory Journal.

The International Agranulocytosis and Aplastic Anemia Study (IAAAS)

T. Hutchinson, M. Kramer, D. Lane, 1988, Journal of clinical epidemiology.

Methylenetetrahydrofolate Reductase 677 C →T Mutation and Coronary Heart Disease Risk in UK Indian Asians

J. Kooner, J. Chambers, P. Ueland, 2000, Arteriosclerosis, thrombosis, and vascular biology.

The Endothelial Cell Protein C Receptor: A Candidate Genetic Risk Factor for Thrombosis

D. Lane, R. Simmonds, 2001, Thrombosis and Haemostasis.

Extravascular fibrin formation and fibrinolysis in a model of inflammation accompanying cellular hypersensitivity

M. K. Jasani, R. Peters, D. Lane, 1986 .

Low Molecular Weight Heparin in Haemodialysis for Chronic Renal Failure: Dose Finding Study of CY222

H. Ireland, D. Lane, A. Pegrum, 1988, Thrombosis and Haemostasis.

The pharmacokinetics of dermatan sulphate MF701 in healthy human volunteers.

C. Forbes, G. Houin, M. Mclaren, 1991, British journal of clinical pharmacology.

Dose Finding Study of a Low Molecular Weight Heparin, Innohep, in Haemodialysis

H. Ireland, D. Lane, A. Flynn, 1991, Thrombosis and Haemostasis.

Heparin and Low Molecular Weight Heparin(oid)s as Anticoagulants in Hemodialysis for Chronic Renal Failure

H. Ireland, D. Lane, A. Flynn, 1989 .

Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation.

H. Ireland, D. Lane, E. Anastassiades, 1986, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Protein S : new insights into its functions

D. Lane, H. M. A. J. Ahnström, 2012 .

Binding of calcium to anticoagulant protein S: role of the fourth EGF module.

Sara Linse, S. Linse, J. Stenflo, 2006, Biochemistry.

Activated protein C cofactor function of protein S : a critical role for Asp 95 in the EGF 1-like domain

B. Dahlbäck, S. Rezende, D. Lane, 2010 .

High Purity Factor IX and Prothrombin Complex Concentrate (PCC): Pharmacokinetics and Evidence that Factor IXa Is the Thrombogenic Trigger in PCC

G. Lowe, A. Rumley, I. Macgregor, 1996, Thrombosis and Haemostasis.

Multifunctional Specificity of the Protein C/Activated Protein C Gla Domain*

B. Dahlbäck, D. Lane, C. Razzari, 2006, Journal of Biological Chemistry.

Protein S Gla-domain mutations causing impaired Ca 2 (cid:1) -induced phospholipid binding and severe functional protein S deﬁciency

S. Rezende, D. Lane, J. Conard, 2002 .